BLAZE is certainly interesting, but the timeline is still quite long. According to ClinicalTrials.gov, the study is expected to be completed in early 2030, and recruitment hasn’t even begun yet. While initial observations might be available sooner, that 50-day period refers to the evaluation cycle for a single patient, not the completion of the entire Phase I trial.
Personally, I would consider BEXERA more important at this stage. It compares the combination of BEX and AZA against AZA treatment without BEX, so it should be the first time we get a clearer view of BEX’s specific impact. If everything proceeds as planned, comparative data could be available well before BLAZE is completed, potentially sometime next year.
I wouldn’t compare the entire PD1 market to the MDS market just yet. BLAZE is investigating a very specific, limited patient population, and the study is open-label without a control group. Positive results could later open up new opportunities for BEX in solid tumors, but at the moment, it is still an early-stage study.
If a licensing agreement or acquisition happens in the coming years, I would consider BEXERA to be clearly more important from a buyer’s perspective. Controlled evidence of the additional benefit of BEX in MDS treatment would reduce clinical uncertainty much more directly. BLAZE might increase the overall value later, but until there is solid data, it is more likely to be an added option than the actual foundation for a deal.